SABS (SAB Biotherapeutics) Beginning Cash Position: $10.50 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SABS SAB Biotherapeutics Inc SABS
30 GF Score
Price $3.67
! 2 Warning Signs
View Full Analysis

What is SAB Biotherapeutics Beginning Cash Position?

SAB Biotherapeutics SABS +1.38% 30 Beginning Cash Position is $10.50 Mil as of Mar. 2026. GuruFocus rates SABS with a GF Score™ of 30/100. The stock has 2 warning signs investors should review.

SAB Biotherapeutics's Beginning Cash Position for the quarter that ended in Mar. 2026 was $10.50 Mil.

SAB Biotherapeutics's quarterly Beginning Cash Position increased from Sep. 2025 ($3.69 Mil) to Dec. 2025 ($29.43 Mil) but then declined from Dec. 2025 ($29.43 Mil) to Mar. 2026 ($10.50 Mil).

SAB Biotherapeutics's annual Beginning Cash Position increased from Dec. 2023 ($15.05 Mil) to Dec. 2024 ($56.57 Mil) but then declined from Dec. 2024 ($56.57 Mil) to Dec. 2025 ($8.90 Mil).

SAB Biotherapeutics Beginning Cash Position Related Terms

SAB Biotherapeutics Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for SAB Biotherapeutics's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SAB Biotherapeutics Beginning Cash Position Chart

SAB Biotherapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial 12.61 39.55 15.05 56.57 8.90

SAB Biotherapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.90 5.64 3.69 29.43 10.50
SABS
30GF Score
SAB Biotherapeutics Inc SABS
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SAB Biotherapeutics Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of $10.50 Mil mean?
SAB Biotherapeutics (SABS) has a Beginning Cash Position of $10.50 Mil as of Mar. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on SAB Biotherapeutics and its competitors.
Is SAB Biotherapeutics' Beginning Cash Position too high?
SAB Biotherapeutics' current Beginning Cash Position is $10.50 Mil. Overall, SAB Biotherapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does SAB Biotherapeutics' Beginning Cash Position compare to SRZN and GLSI?
SAB Biotherapeutics' Beginning Cash Position of $10.50 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on SAB Biotherapeutics and its competitors. SAB Biotherapeutics's current Beginning Cash Position is $10.50 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SAB Biotherapeutics stock overvalued right now?
SAB Biotherapeutics (SABS) has a current Beginning Cash Position of $10.50 Mil. The current Beginning Cash Position is $10.50 Mil. SAB Biotherapeutics' overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For SAB Biotherapeutics (SABS), the current Beginning Cash Position is $10.50 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

SAB Biotherapeutics Business Description

Address 777 West 41st Street, Suite 401, Miami Beach, FL, USA, 33140
SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.
30GF Score

Get the complete analysis for SABS

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.67
Price